Ablynx is a Belgian biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments.

Today, the Company has approximately 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease.

Running 1 Phase III study and 4 Phase II studies
>40 in early development

Unique and powerful
technology platform

>500 patents
granted and pending

8 pharma partners
across the globe

>450 employees
20 nationalities

Listed on Euronext Brussels
& Nasdaq (ticker: ABLX)

Ablynx has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck KGaA, Novo Nordisk, Sanofi and Taisho Pharmaceutical Co., Ltd.

Boehringer Ingelheim
Merck KGaA
Merck Research Laboratories
Novo Nordisk
Taisho Pharmaceutical Co., Ltd.